Health Care [ 7/12 ] | Biotechnology [ 56/74 ]
NASDAQ | Common Stock
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases.
Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease.
The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 19, 26 | -0.18 Increased by +30.77% | -0.26 Increased by +31.11% |
| Mar 26, 26 | -0.27 Increased by +18.18% | -0.25 Decreased by -8.39% |
| Nov 6, 25 | -0.21 Increased by +34.66% | -0.27 Increased by +22.22% |
| Aug 12, 25 | -0.27 Increased by +22.86% | -0.31 Increased by +12.90% |
| May 7, 25 | -0.26 Increased by +23.53% | -0.34 Increased by +23.91% |
| Mar 25, 25 | -0.33 Increased by 0.00% | -0.34 Increased by +1.52% |
| Nov 5, 24 | -0.32 Increased by +17.59% | -0.35 Increased by +8.17% |
| Aug 8, 24 | -0.35 Decreased by -9.37% | -0.34 Decreased by -2.94% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 0.00 Decreased by -100.00% | -22.56 M Decreased by -15.26% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 25 | 26.00 K Increased by +420.00% | -27.36 M Decreased by -18.02% | Decreased by -105.22 K% Increased by +77.30% |
| Sep 30, 25 | 5.00 K Increased by 0.00% | -19.01 M Increased by +16.77% | Decreased by -380.28 K% Increased by +16.77% |
| Jun 30, 25 | 5.00 K Increased by 0.00% | -22.15 M Increased by +10.12% | Decreased by -442.92 K% Increased by +10.12% |
| Mar 31, 25 | 5.00 K Increased by 0.00% | -19.57 M Increased by +19.75% | Decreased by -391.50 K% Increased by +19.75% |
| Dec 31, 24 | 5.00 K Decreased by -86.49% | -23.18 M Increased by +26.74% | Decreased by -463.60 K% Decreased by -442.12% |
| Sep 30, 24 | 5.00 K Decreased by -98.62% | -22.84 M Decreased by -10.52% | Decreased by -456.90 K% Decreased by -7.90 K% |
| Jun 30, 24 | 5.00 K Decreased by -16.67% | -24.64 M Decreased by -53.42% | Decreased by -492.80 K% Decreased by -84.10% |